Teachers Advisors LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 535,909 shares of the medical research company’s stock after selling 6,041 shares during the quarter. Teachers Advisors LLC’s holdings in Thermo Fisher Scientific were worth $101,758,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Icon Wealth Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $105,000. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $106,000. Keeler Thomas Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $106,000. Virtue Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $127,000. Finally, Premia Global Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $131,000. Institutional investors own 87.67% of the company’s stock.
Thermo Fisher Scientific Inc. (NYSE TMO) opened at $215.12 on Wednesday. Thermo Fisher Scientific Inc. has a 1 year low of $151.74 and a 1 year high of $226.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.34. The company has a market cap of $87,384.02, a P/E ratio of 38.41, a price-to-earnings-growth ratio of 1.59 and a beta of 1.15.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter last year, the firm earned $2.41 EPS. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.71%.
TMO has been the subject of a number of analyst reports. Leerink Swann reiterated an “outperform” rating and set a $200.00 price target (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. BTIG Research initiated coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 price target for the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Finally, Barclays lifted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $220.50.
In related news, SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total value of $7,321,941.90. Following the sale, the senior vice president now owns 60,471 shares of the company’s stock, valued at approximately $13,285,478.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,827 shares of company stock worth $20,193,272. Insiders own 0.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/14/teachers-advisors-llc-trims-stake-in-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.